title: Antibody response following hepatitis B vaccination in peritoneal dialysis patients: does normalized urea clearance matter?
abstract: OBJECTIVE
  Data on the factors that contribute to the antibody response to hepatitis B virus vaccination in peritoneal dialysis patients are scarce. The current study was conducted on a group of peritoneal dialysis patients to learn how the response to hepatitis B virus vaccination varies according to the patient's clearance of urea normalized to total body water (Kt/V).
  
  
  METHODS
  A convenience sample of 33 peritoneal dialysis patients (13 women and 20 men, with a mean age of 49 ± 12 years) was administered double doses (20 μg IM in each deltoid muscle) of recombinant hepatitis B vaccine at 0, 1, 2, and 6 months. Response to immunization was measured at one to three months after the final dose of vaccine. The subjects were divided into groups according to the level of antibodies to hepatitis B surface antigen (anti-HBs), including non-responders ( < 10 IU/L), weak responders (10-100 IU/L), and good responders ( > 100 IU/L).
  
  
  RESULTS
  Among non-responders, weak responders, and good responders, significant differences were found in age (54 ± 12 vs. 56 ± 9 vs. 45 ± 12 years, respectively; p = 0.049) and recombinant human erythropoietin use (20 vs. 29 vs. 76%, respectively; p = 0.016). No significant differences in weekly total Kt/V (p = 0.704), weekly peritoneal Kt/V (p = 0.064) and residual glomerular filtration rate (p = 0.355) were found across the three groups.
  
  
  CONCLUSIONS
  Delivered clearance measured by weekly peritoneal Kt/V and total clearance measured by weekly total Kt/V did not predict the response to hepatitis B virus vaccination in patients on peritoneal dialysis.
authors.affiliation: Department of Nephrology, Kocaeli University School of Medicine, Turkey. dervisoglue@yahoo.com
authors.forename: Erkan
authors.initials: E
authors.lastname: Dervisoglu
authors.forename: Melih
authors.initials: M
authors.lastname: Simsek
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yilmaz
mesh_terms: D004305:Dose-Response Relationship, Drug; D004812:Epidemiologic Methods; D005260:Female; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D013997:Time Factors; D014508:Urea / Q000378:metabolism*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014508:Urea